Insider-Transaktionen

EDGAR

Celularity Inc

Von Direktoren, Führungskräften und 10-%-Eignern auf den SEC-Formularen 3, 4 und 5 gemeldete Transaktionen, aus dem XML jeder Einreichung gelesen. Codes und ihr Wortlaut stammen von der SEC.

Das Formular 4 ist innerhalb von zwei Geschäftstagen nach der Transaktion einzureichen; die jüngsten Geschäfte sind daher möglicherweise noch nicht gemeldet.

Zeitfenster: Transaktionen ab dem 17. Nov. 2025.

Käufe am offenen Markt (Code P)
0 Transaktionen, — Aktien
Verkäufe am offenen Markt (Code S)
0 Transaktionen, — Aktien

Die Summen addieren die aufgeführten eingereichten Transaktionen; sie zählen das Gemeldete und messen keine Richtung.

1–50 von 53 angezeigt

Insider-Transaktionen, neueste zuerst, wie auf den SEC-Formularen 3, 4 und 5 eingereicht
DatumMeldende PersonCodeErworben oder veräußertAktienPreis je Aktie, wie eingereichtWert (abgeleitet)Aktien danach im BesitzDirekt oder indirektKästchen zu Rule 10b5-1AnmerkungenQuelle
23. Sept. 2026 Eingereicht am 25. Sept. 2026Barach Philip Alan Director · 10% owner
J

Other acquisition or disposition (describe transaction)

Derivatives Wertpapier: Convertible Notes — Basiswert Class A Common Stock (2.000.000) — Ausübungspreis 1.50
Erworben (A)192.771——2.000.000Indirekt (I) See FootnoteNein
F1, F2
  • F1 Represents the amendment and restatement on September 23, 2026 of an existing convertible note of the Issuer in which the applicable conversion price was reduced from $1.66 per share to $1.50 per share and the maturity date was extended from December 31, 2026 to September 23, 2028, as a result of which the number of shares issuable upon conversion of such note was increased from 1,807,229 to 2,000,000. No additional consideration was paid in connection with such amendment and restatement.
  • F2 The Philip and Daniele Barach Family Trust (the Trust) is or was the direct owner of all securities reported herein. The Reporting Person is a trustee of the Trust and has independent power to vote and dispose of all securities held by the Trust. The Reporting Person may be deemed to be an indirect beneficial owner of the securities held by the Trust, and the Reporting Person disclaims beneficial ownership of the securities held by the Trust except to the extent of the Reporting Person's pecuniary interest therein.
Einreichung öffnen 0001104659-26-111026 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
23. Sept. 2026 Eingereicht am 25. Sept. 2026Barach Philip Alan Director · 10% owner
J

Other acquisition or disposition (describe transaction)

Derivatives Wertpapier: Convertible Notes — Basiswert Class A Common Stock (2.140.000) — Ausübungspreis 1.50
Erworben (A)2.140.000——2.140.000Indirekt (I) See FootnoteNein
F4, F2
  • F4 Represents shares of Class A Common Stock issuable upon the conversion of $3,210,000 in aggregate principal amount of convertible notes (the September 2026 Notes) that the Reporting Person purchased from the Issuer for such an amount of cash on September 23, 2026.
  • F2 The Philip and Daniele Barach Family Trust (the Trust) is or was the direct owner of all securities reported herein. The Reporting Person is a trustee of the Trust and has independent power to vote and dispose of all securities held by the Trust. The Reporting Person may be deemed to be an indirect beneficial owner of the securities held by the Trust, and the Reporting Person disclaims beneficial ownership of the securities held by the Trust except to the extent of the Reporting Person's pecuniary interest therein.
Einreichung öffnen 0001104659-26-111026 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
23. Sept. 2026 Eingereicht am 25. Sept. 2026Barach Philip Alan Director · 10% owner
J

Other acquisition or disposition (describe transaction)

Derivatives Wertpapier: Warrants — Basiswert Class A Common Stock (1.177.000) — Ausübungspreis 1.50
Erworben (A)1.177.000——1.177.000Indirekt (I) See FootnoteNein
F5, F4, F2
  • F5 Represents shares of Class A Common Stock issuable upon the exercise of 1,177,000 warrants that the Reporting Person obtained from the Issuer in connection with the issuance of the September 2026 Notes. No additional consideration was paid in connection with the issuance of such warrants.
  • F4 Represents shares of Class A Common Stock issuable upon the conversion of $3,210,000 in aggregate principal amount of convertible notes (the September 2026 Notes) that the Reporting Person purchased from the Issuer for such an amount of cash on September 23, 2026.
  • F2 The Philip and Daniele Barach Family Trust (the Trust) is or was the direct owner of all securities reported herein. The Reporting Person is a trustee of the Trust and has independent power to vote and dispose of all securities held by the Trust. The Reporting Person may be deemed to be an indirect beneficial owner of the securities held by the Trust, and the Reporting Person disclaims beneficial ownership of the securities held by the Trust except to the extent of the Reporting Person's pecuniary interest therein.
Einreichung öffnen 0001104659-26-111026 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
23. Sept. 2026 Eingereicht am 25. Sept. 2026Barach Philip Alan Director · 10% owner
J

Other acquisition or disposition (describe transaction)

Derivatives Wertpapier: Convertible Notes — Basiswert Class A Common Stock (1.457.765) — Ausübungspreis 2.00
Erworben (A)1.457.765——1.457.765Indirekt (I) See FootnoteNein
F6, F2
  • F6 Represents shares of Class A Common Stock issuable upon the conversion of up to $2,915,531 in aggregate principal amount of convertible notes (the September 2027 Notes) that the Reporting Person has the option to purchase from the Issuer at any time until September 30, 2027. Such option is a contractual right granted by the Issuer in connection with the issuance of the September 2026 Notes for, which no additional consideration was paid.
  • F2 The Philip and Daniele Barach Family Trust (the Trust) is or was the direct owner of all securities reported herein. The Reporting Person is a trustee of the Trust and has independent power to vote and dispose of all securities held by the Trust. The Reporting Person may be deemed to be an indirect beneficial owner of the securities held by the Trust, and the Reporting Person disclaims beneficial ownership of the securities held by the Trust except to the extent of the Reporting Person's pecuniary interest therein.
Einreichung öffnen 0001104659-26-111026 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
23. Sept. 2026 Eingereicht am 25. Sept. 2026Barach Philip Alan Director · 10% owner
J

Other acquisition or disposition (describe transaction)

Derivatives Wertpapier: Warrants — Basiswert Class A Common Stock (1.457.765) — Ausübungspreis 2.00
Erworben (A)1.457.765——1.457.765Indirekt (I) See FootnoteNein
F7, F6, F2
  • F7 Represents shares of Class A Common Stock issuable upon the exercise of up to 1,457,765 warrants that the Reporting Person has the option to obtain from the Issuer for in connection with the issuance of September 2027 Notes at any time until September 30, 2027. Such option is a contractual right granted by the Issuer in connection with the issuance of the September 2026 Notes for, which no additional consideration was paid.
  • F6 Represents shares of Class A Common Stock issuable upon the conversion of up to $2,915,531 in aggregate principal amount of convertible notes (the September 2027 Notes) that the Reporting Person has the option to purchase from the Issuer at any time until September 30, 2027. Such option is a contractual right granted by the Issuer in connection with the issuance of the September 2026 Notes for, which no additional consideration was paid.
  • F2 The Philip and Daniele Barach Family Trust (the Trust) is or was the direct owner of all securities reported herein. The Reporting Person is a trustee of the Trust and has independent power to vote and dispose of all securities held by the Trust. The Reporting Person may be deemed to be an indirect beneficial owner of the securities held by the Trust, and the Reporting Person disclaims beneficial ownership of the securities held by the Trust except to the extent of the Reporting Person's pecuniary interest therein.
Einreichung öffnen 0001104659-26-111026 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
23. Sept. 2026 Eingereicht am 25. Sept. 2026Barach Daniele Wolf 10% owner
J

Other acquisition or disposition (describe transaction)

Derivatives Wertpapier: Convertible Notes — Basiswert Class A Common Stock (2.000.000) — Ausübungspreis 1.50
Erworben (A)192.771——2.000.000Indirekt (I) See FootnoteNein
F1, F2
  • F1 Represents the amendment and restatement on September 23, 2026 of an existing convertible note of the Issuer in which the applicable conversion price was reduced from $1.66 per share to $1.50 per share and the maturity date was extended from December 31, 2026 to September 23, 2028, as a result of which the number of shares issuable upon conversion of such note was increased from 1,807,229 to 2,000,000. No additional consideration was paid in connection with such amendment and restatement.
  • F2 The Philip and Daniele Barach Family Trust (the Trust) is or was the direct owner of all securities reported herein. The Reporting Person is a trustee of the Trust and has independent power to vote and dispose of all securities held by the Trust. The Reporting Person may be deemed to be an indirect beneficial owner of the securities held by the Trust, and the Reporting Person disclaims beneficial ownership of the securities held by the Trust except to the extent of the Reporting Person's pecuniary interest therein.
Einreichung öffnen 0001104659-26-111027 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
23. Sept. 2026 Eingereicht am 25. Sept. 2026Barach Daniele Wolf 10% owner
J

Other acquisition or disposition (describe transaction)

Derivatives Wertpapier: Convertible Notes — Basiswert Class A Common Stock (2.140.000) — Ausübungspreis 1.50
Erworben (A)2.140.000——2.140.000Indirekt (I) See FootnoteNein
F4, F2
  • F4 Represents shares of Class A Common Stock issuable upon the conversion of $3,210,000 in aggregate principal amount of convertible notes (the September 2026 Notes) that the Reporting Person purchased from the Issuer for such an amount of cash on September 23, 2026.
  • F2 The Philip and Daniele Barach Family Trust (the Trust) is or was the direct owner of all securities reported herein. The Reporting Person is a trustee of the Trust and has independent power to vote and dispose of all securities held by the Trust. The Reporting Person may be deemed to be an indirect beneficial owner of the securities held by the Trust, and the Reporting Person disclaims beneficial ownership of the securities held by the Trust except to the extent of the Reporting Person's pecuniary interest therein.
Einreichung öffnen 0001104659-26-111027 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
23. Sept. 2026 Eingereicht am 25. Sept. 2026Barach Daniele Wolf 10% owner
J

Other acquisition or disposition (describe transaction)

Derivatives Wertpapier: Warrants — Basiswert Class A Common Stock (1.177.000) — Ausübungspreis 1.50
Erworben (A)1.177.000——1.177.000Indirekt (I) See FootnoteNein
F5, F4, F2
  • F5 Represents shares of Class A Common Stock issuable upon the exercise of 1,177,000 warrants that the Reporting Person obtained from the Issuer in connection with the issuance of the September 2026 Notes. No additional consideration was paid in connection with the issuance of such warrants.
  • F4 Represents shares of Class A Common Stock issuable upon the conversion of $3,210,000 in aggregate principal amount of convertible notes (the September 2026 Notes) that the Reporting Person purchased from the Issuer for such an amount of cash on September 23, 2026.
  • F2 The Philip and Daniele Barach Family Trust (the Trust) is or was the direct owner of all securities reported herein. The Reporting Person is a trustee of the Trust and has independent power to vote and dispose of all securities held by the Trust. The Reporting Person may be deemed to be an indirect beneficial owner of the securities held by the Trust, and the Reporting Person disclaims beneficial ownership of the securities held by the Trust except to the extent of the Reporting Person's pecuniary interest therein.
Einreichung öffnen 0001104659-26-111027 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
23. Sept. 2026 Eingereicht am 25. Sept. 2026Barach Daniele Wolf 10% owner
J

Other acquisition or disposition (describe transaction)

Derivatives Wertpapier: Convertible Notes — Basiswert Class A Common Stock (1.457.765) — Ausübungspreis 2.00
Erworben (A)1.457.765——1.457.765Indirekt (I) See FootnoteNein
F6, F2
  • F6 Represents shares of Class A Common Stock issuable upon the conversion of up to $2,915,531 in aggregate principal amount of convertible notes (the September 2027 Notes) that the Reporting Person has the option to purchase from the Issuer at any time until September 30, 2027. Such option is a contractual right granted by the Issuer in connection with the issuance of the September 2026 Notes for, which no additional consideration was paid.
  • F2 The Philip and Daniele Barach Family Trust (the Trust) is or was the direct owner of all securities reported herein. The Reporting Person is a trustee of the Trust and has independent power to vote and dispose of all securities held by the Trust. The Reporting Person may be deemed to be an indirect beneficial owner of the securities held by the Trust, and the Reporting Person disclaims beneficial ownership of the securities held by the Trust except to the extent of the Reporting Person's pecuniary interest therein.
Einreichung öffnen 0001104659-26-111027 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
23. Sept. 2026 Eingereicht am 25. Sept. 2026Barach Daniele Wolf 10% owner
J

Other acquisition or disposition (describe transaction)

Derivatives Wertpapier: Warrants — Basiswert Class A Common Stock (1.457.765) — Ausübungspreis 2.00
Erworben (A)1.457.765——1.457.765Indirekt (I) See FootnoteNein
F7, F6, F2
  • F7 Represents shares of Class A Common Stock issuable upon the exercise of up to 1,457,765 warrants that the Reporting Person has the option to obtain from the Issuer for in connection with the issuance of September 2027 Notes at any time until September 30, 2027. Such option is a contractual right granted by the Issuer in connection with the issuance of the September 2026 Notes for, which no additional consideration was paid.
  • F6 Represents shares of Class A Common Stock issuable upon the conversion of up to $2,915,531 in aggregate principal amount of convertible notes (the September 2027 Notes) that the Reporting Person has the option to purchase from the Issuer at any time until September 30, 2027. Such option is a contractual right granted by the Issuer in connection with the issuance of the September 2026 Notes for, which no additional consideration was paid.
  • F2 The Philip and Daniele Barach Family Trust (the Trust) is or was the direct owner of all securities reported herein. The Reporting Person is a trustee of the Trust and has independent power to vote and dispose of all securities held by the Trust. The Reporting Person may be deemed to be an indirect beneficial owner of the securities held by the Trust, and the Reporting Person disclaims beneficial ownership of the securities held by the Trust except to the extent of the Reporting Person's pecuniary interest therein.
Einreichung öffnen 0001104659-26-111027 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
23. Sept. 2026 Eingereicht am 25. Sept. 2026Philip Daniele Barach Family Trust 10% owner
J

Other acquisition or disposition (describe transaction)

Derivatives Wertpapier: Convertible Notes — Basiswert Class A Common Stock (2.000.000) — Ausübungspreis 1.50
Erworben (A)192.771——2.000.000Direkt (D) Nein
F1
  • F1 Represents the amendment and restatement on September 23, 2026 of an existing convertible note of the Issuer in which the applicable conversion price was reduced from $1.66 per share to $1.50 per share and the maturity date was extended from December 31, 2026 to September 23, 2028, as a result of which the number of shares issuable upon conversion of such note was increased from 1,807,229 to 2,000,000. No additional consideration was paid in connection with such amendment and restatement.
Einreichung öffnen 0001104659-26-111028 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
23. Sept. 2026 Eingereicht am 25. Sept. 2026Philip Daniele Barach Family Trust 10% owner
J

Other acquisition or disposition (describe transaction)

Derivatives Wertpapier: Convertible Notes — Basiswert Class A Common Stock (2.140.000) — Ausübungspreis 1.50
Erworben (A)2.140.000——2.140.000Direkt (D) Nein
F3
  • F3 Represents shares of Class A Common Stock issuable upon the conversion of $3,210,000 in aggregate principal amount of convertible notes (the September 2026 Notes) that the Reporting Person purchased from the Issuer for such an amount of cash on September 23, 2026.
Einreichung öffnen 0001104659-26-111028 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
23. Sept. 2026 Eingereicht am 25. Sept. 2026Philip Daniele Barach Family Trust 10% owner
J

Other acquisition or disposition (describe transaction)

Derivatives Wertpapier: Warrants — Basiswert Class A Common Stock (1.177.000) — Ausübungspreis 1.50
Erworben (A)1.177.000——1.177.000Direkt (D) Nein
F4, F3
  • F4 Represents shares of Class A Common Stock issuable upon the exercise of 1,177,000 warrants that the Reporting Person obtained from the Issuer in connection with the issuance of the September 2026 Notes. No additional consideration was paid in connection with the issuance of such warrants.
  • F3 Represents shares of Class A Common Stock issuable upon the conversion of $3,210,000 in aggregate principal amount of convertible notes (the September 2026 Notes) that the Reporting Person purchased from the Issuer for such an amount of cash on September 23, 2026.
Einreichung öffnen 0001104659-26-111028 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
23. Sept. 2026 Eingereicht am 25. Sept. 2026Philip Daniele Barach Family Trust 10% owner
J

Other acquisition or disposition (describe transaction)

Derivatives Wertpapier: Convertible Notes — Basiswert Class A Common Stock (1.457.765) — Ausübungspreis 2.00
Erworben (A)1.457.765——1.457.765Direkt (D) Nein
F5
  • F5 Represents shares of Class A Common Stock issuable upon the conversion of up to $2,915,531 in aggregate principal amount of convertible notes (the September 2027 Notes) that the Reporting Person has the option to purchase from the Issuer at any time until September 30, 2027. Such option is a contractual right granted by the Issuer in connection with the issuance of the September 2026 Notes for, which no additional consideration was paid.
Einreichung öffnen 0001104659-26-111028 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
23. Sept. 2026 Eingereicht am 25. Sept. 2026Philip Daniele Barach Family Trust 10% owner
J

Other acquisition or disposition (describe transaction)

Derivatives Wertpapier: Warrants — Basiswert Class A Common Stock (1.457.765) — Ausübungspreis 2.00
Erworben (A)1.457.765——1.457.765Direkt (D) Nein
F6, F5
  • F6 Represents shares of Class A Common Stock issuable upon the exercise of up to 1,457,765 warrants that the Reporting Person has the option to obtain from the Issuer for in connection with the issuance of September 2027 Notes at any time until September 30, 2027. Such option is a contractual right granted by the Issuer in connection with the issuance of the September 2026 Notes for, which no additional consideration was paid.
  • F5 Represents shares of Class A Common Stock issuable upon the conversion of up to $2,915,531 in aggregate principal amount of convertible notes (the September 2027 Notes) that the Reporting Person has the option to purchase from the Issuer at any time until September 30, 2027. Such option is a contractual right granted by the Issuer in connection with the issuance of the September 2026 Notes for, which no additional consideration was paid.
Einreichung öffnen 0001104659-26-111028 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
19. Juni 2026 Eingereicht am 23. Juni 2026Barach Daniele Wolf 10% owner
J

Other acquisition or disposition (describe transaction)

Derivatives Wertpapier: Convertible Notes — Basiswert Class A Common Stock (1.204.819) — Ausübungspreis 1.66
Veräußert (D)1.204.819——0Indirekt (I) See FootnoteNein
F1, F3
  • F1 Represented shares of Class A Common Stock issuable upon the conversion of up to $2,000,000 in aggregate principal amount of convertible notes (the Notes) that the Reporting Person had the option to purchase from the Issuer at any time until June 19, 2026. The option to purchase such Notes expired pursuant to its terms on June 19, 2026, and no consideration was paid in connection with such expiration.
  • F3 The Philip Daniele Barach Family Trust (the Trust) is or was the direct owner of all securities reported herein. The Reporting Person is a trustee of the Trust and has independent power to vote and dispose of all securities held by the Trust. The Reporting Person may be deemed to be an indirect beneficial owner of the securities held by the Trust, and the Reporting Person disclaims beneficial ownership of the securities held by the Trust except to the extent of the Reporting Person's pecuniary interest therein.
Einreichung öffnen 0001104659-26-076681 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
19. Juni 2026 Eingereicht am 23. Juni 2026Barach Daniele Wolf 10% owner
J

Other acquisition or disposition (describe transaction)

Derivatives Wertpapier: Warrants — Basiswert Class A Common Stock (839.160) — Ausübungspreis 2.00
Veräußert (D)839.160——0Indirekt (I) See FootnoteNein
F2, F1, F3
  • F2 Represented shares of Class A Common Stock issuable upon the exercise of up to 839,160 warrants (the Warrants) that the Reporting Person had the option to obtain from the Issuer in connection with the purchase by the Reporting Person of the Notes at any time until June 19, 2026. Because the Reporting Person's option to purchase the Notes expired pursuant to its terms on June 19, 2026, the ability to obtain such Warrants also expired on such date.
  • F1 Represented shares of Class A Common Stock issuable upon the conversion of up to $2,000,000 in aggregate principal amount of convertible notes (the Notes) that the Reporting Person had the option to purchase from the Issuer at any time until June 19, 2026. The option to purchase such Notes expired pursuant to its terms on June 19, 2026, and no consideration was paid in connection with such expiration.
  • F3 The Philip Daniele Barach Family Trust (the Trust) is or was the direct owner of all securities reported herein. The Reporting Person is a trustee of the Trust and has independent power to vote and dispose of all securities held by the Trust. The Reporting Person may be deemed to be an indirect beneficial owner of the securities held by the Trust, and the Reporting Person disclaims beneficial ownership of the securities held by the Trust except to the extent of the Reporting Person's pecuniary interest therein.
Einreichung öffnen 0001104659-26-076681 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
19. Juni 2026 Eingereicht am 23. Juni 2026Philip Daniele Barach Family Trust 10% owner
J

Other acquisition or disposition (describe transaction)

Derivatives Wertpapier: Convertible Notes — Basiswert Class A Common Stock (1.204.819) — Ausübungspreis 1.66
Veräußert (D)1.204.819——0Direkt (D) Nein
F1
  • F1 Represented shares of Class A Common Stock issuable upon the conversion of up to $2,000,000 in aggregate principal amount of convertible notes (the Notes) that the Reporting Person had the option to purchase from the Issuer at any time until June 19, 2026. The option to purchase such Notes expired pursuant to its terms on June 19, 2026, and no consideration was paid in connection with such expiration.
Einreichung öffnen 0001104659-26-076683 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
19. Juni 2026 Eingereicht am 23. Juni 2026Philip Daniele Barach Family Trust 10% owner
J

Other acquisition or disposition (describe transaction)

Derivatives Wertpapier: Warrants — Basiswert Class A Common Stock (839.160) — Ausübungspreis 2.00
Veräußert (D)839.160——0Direkt (D) Nein
F2, F1
  • F2 Represented shares of Class A Common Stock issuable upon the exercise of up to 839,160 warrants (the Warrants) that the Reporting Person had the option to obtain from the Issuer in connection with the purchase by the Reporting Person of the Notes at any time until June 19, 2026. Because the Reporting Person's option to purchase the Notes expired pursuant to its terms on June 19, 2026, the ability to obtain such Warrants also expired on such date.
  • F1 Represented shares of Class A Common Stock issuable upon the conversion of up to $2,000,000 in aggregate principal amount of convertible notes (the Notes) that the Reporting Person had the option to purchase from the Issuer at any time until June 19, 2026. The option to purchase such Notes expired pursuant to its terms on June 19, 2026, and no consideration was paid in connection with such expiration.
Einreichung öffnen 0001104659-26-076683 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
19. Juni 2026 Eingereicht am 23. Juni 2026Barach Philip Alan 10% owner
J

Other acquisition or disposition (describe transaction)

Derivatives Wertpapier: Convertible Notes — Basiswert Class A Common Stock (1.204.819) — Ausübungspreis 1.66
Veräußert (D)1.204.819——0Indirekt (I) See FootnoteNein
F1, F3
  • F1 Represented shares of Class A Common Stock issuable upon the conversion of up to $2,000,000 in aggregate principal amount of convertible notes (the Notes) that the Reporting Person had the option to purchase from the Issuer at any time until June 19, 2026. The option to purchase such Notes expired pursuant to its terms on June 19, 2026, and no consideration was paid in connection with such expiration.
  • F3 The Philip Daniele Barach Family Trust (the Trust) is or was the direct owner of all securities reported herein. The Reporting Person is a trustee of the Trust and has independent power to vote and dispose of all securities held by the Trust. The Reporting Person may be deemed to be an indirect beneficial owner of the securities held by the Trust, and the Reporting Person disclaims beneficial ownership of the securities held by the Trust except to the extent of the Reporting Person's pecuniary interest therein.
Einreichung öffnen 0001104659-26-076682 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
19. Juni 2026 Eingereicht am 23. Juni 2026Barach Philip Alan 10% owner
J

Other acquisition or disposition (describe transaction)

Derivatives Wertpapier: Warrants — Basiswert Class A Common Stock (839.160) — Ausübungspreis 2.00
Veräußert (D)839.160——0Indirekt (I) See FootnoteNein
F2, F1, F3
  • F2 Represented shares of Class A Common Stock issuable upon the exercise of up to 839,160 warrants (the Warrants) that the Reporting Person had the option to obtain from the Issuer in connection with the purchase by the Reporting Person of the Notes at any time until June 19, 2026. Because the Reporting Person's option to purchase the Notes expired pursuant to its terms on June 19, 2026, the ability to obtain such Warrants also expired on such date.
  • F1 Represented shares of Class A Common Stock issuable upon the conversion of up to $2,000,000 in aggregate principal amount of convertible notes (the Notes) that the Reporting Person had the option to purchase from the Issuer at any time until June 19, 2026. The option to purchase such Notes expired pursuant to its terms on June 19, 2026, and no consideration was paid in connection with such expiration.
  • F3 The Philip Daniele Barach Family Trust (the Trust) is or was the direct owner of all securities reported herein. The Reporting Person is a trustee of the Trust and has independent power to vote and dispose of all securities held by the Trust. The Reporting Person may be deemed to be an indirect beneficial owner of the securities held by the Trust, and the Reporting Person disclaims beneficial ownership of the securities held by the Trust except to the extent of the Reporting Person's pecuniary interest therein.
Einreichung öffnen 0001104659-26-076682 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
13. Apr. 2026 Eingereicht am 15. Apr. 2026Hariri Robert J Director · Officer: Chief Executive Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Class A Common Stock
Erworben (A)3.2810—2.854.735Direkt (D) Nein
F1
  • F1 Represents the conversion upon vesting of restricted stock units (RSUs) into Class A Common Stock. On April 13, 2022, the reporting person was granted 13,123 RSUs, 25% of which vested on April 13, 2026. Such RSUs were previously reported in Table II on a Form 4 filed with the SEC on April 28, 2022.
Einreichung öffnen 0001493152-26-016832 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
13. Apr. 2026 Eingereicht am 15. Apr. 2026Hariri Robert J Director · Officer: Chief Executive Officer
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Class A Common Stock
Veräußert (D)1.1821,28
1.512,96

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 1512.96.

2.853.553Direkt (D) Nein
F2
  • F2 This line reflects the tax withholding on the vesting of RSUs that vested on April 13, 2026.
Einreichung öffnen 0001493152-26-016832 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
13. Apr. 2026 Eingereicht am 15. Apr. 2026Hariri Robert J Director · Officer: Chief Executive Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivatives Wertpapier: Restricted Stock Units — Basiswert Class A Common Stock (3.281)
Veräußert (D)3.2810—0Direkt (D) Nein
F3, F4
  • F3 Each restricted stock unit is the economic equivalent of one share of Celularity Inc. Class A Common Stock.
  • F4 On April 13, 2022, the reporting person was granted 13,123 RSUs, 25% of which vested on April 13, 2026. The Class A Common Stock into which such vested RSUs converted on April 13, 2026 is reported in Table I on this Form 4.
Einreichung öffnen 0001493152-26-016832 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
13. Apr. 2026 Eingereicht am 15. Apr. 2026Haines John R Officer: Senior Exec Vice President
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Class A Common Stock
Erworben (A)1.6410—30.762Direkt (D) Nein
F1
  • F1 Represents the conversion upon vesting of restricted stock units (RSUs) into Class A common stock. On April 13, 2022, the reporting person was granted 6,562 RSUs, 25% of which vested on April 13, 2026. Such RSUs were previously reported in Table II on a Form 4 filed with the SEC on April 28, 2022.
Einreichung öffnen 0001493152-26-016833 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
13. Apr. 2026 Eingereicht am 15. Apr. 2026Haines John R Officer: Senior Exec Vice President
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Class A Common Stock
Veräußert (D)5831,28
746,24

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 746.24.

30.179Direkt (D) Nein
F2
  • F2 This line reflects the tax withholding on the vesting of RSUs that vested on April 13, 2026.
Einreichung öffnen 0001493152-26-016833 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
13. Apr. 2026 Eingereicht am 15. Apr. 2026Haines John R Officer: Senior Exec Vice President
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivatives Wertpapier: Restricted Stock Units — Basiswert Class A Common Stock (1.641)
Veräußert (D)1.6410—0Direkt (D) Nein
F3, F4
  • F3 Each restricted stock unit is the economic equivalent of one share of Celularity Inc. Class A Common Stock.
  • F4 On April 13, 2022, the reporting person was granted 6,562 RSUs, 25% of which vested on April 13, 2026. The Class a common stock into which such vested RSUs converted on April 13, 2026 is reported in Table I on this Form 4.
Einreichung öffnen 0001493152-26-016833 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
13. Apr. 2026 Eingereicht am 15. Apr. 2026Brigido Stephen Officer: Pres., Functional Regeneration
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Class A Common Stock
Erworben (A)8210—9.742Direkt (D) Nein
F1
  • F1 Represents the conversion upon vesting of restricted stock units (RSUs) into Class A Common Stock. On April 13, 2022, the reporting person was granted 3,281 RSUs, 25% of which vested on April 13, 2026. Such RSUs were previously reported in Table II on a Form 4 filed with the SEC on April 28, 2022.
Einreichung öffnen 0001493152-26-016834 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
13. Apr. 2026 Eingereicht am 15. Apr. 2026Brigido Stephen Officer: Pres., Functional Regeneration
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Class A Common Stock
Veräußert (D)2681,28
343,04

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 343.04.

9.474Direkt (D) Nein
F2
  • F2 This line reflects the tax withholding on the vesting of RSUs that vested on April 13, 2026.
Einreichung öffnen 0001493152-26-016834 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
13. Apr. 2026 Eingereicht am 15. Apr. 2026Brigido Stephen Officer: Pres., Functional Regeneration
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivatives Wertpapier: Restricted Stock Units — Basiswert Class A Common Stock (821)
Veräußert (D)8210—0Direkt (D) Nein
F3, F4
  • F3 Each restricted stock unit is the economic equivalent of one share of Celularity Inc. Class A Common Stock.
  • F4 On April 13, 2022, the reporting person was granted 3,281 RSUs, 25% of which vested on April 13, 2026. The Class A Common Stock into which such vested RSUs converted on April 13, 2026 is reported in Table I on this Form 4.
Einreichung öffnen 0001493152-26-016834 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
12. Jan. 2026 Eingereicht am 15. Jan. 2026Ling Geoffrey M.D. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Class A Common Stock
Erworben (A)19.2310,00
0

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 0.00.

256.026Direkt (D) Nein
F1, F2
  • F1 These shares represent restricted stock units (RSUs) granted under the Celularity Inc. 2021 Equity Incentive Plan (the 2021 Plan), with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest immediately upon grant.
  • F2 Includes 19,231 RSUs granted under the 2021 Plan, with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest immediately upon grant.
Einreichung öffnen 0001493152-26-002424 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
12. Jan. 2026 Eingereicht am 15. Jan. 2026Parks Diane L. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Class A Common Stock
Erworben (A)30.0000,00
0

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 0.00.

520.021Direkt (D) Nein
F1, F2
  • F1 These shares represent restricted stock units (RSUs) granted under the Celularity Inc. 2021 Equity Incentive Plan (the 2021 Plan), with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest immediately upon grant.
  • F2 Includes 30,000 RSUs granted under the 2021 Plan, with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest immediately upon grant.
Einreichung öffnen 0001493152-26-002427 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
12. Jan. 2026 Eingereicht am 15. Jan. 2026LeVien Vincent Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Class A Common Stock
Erworben (A)28.8470,00
0

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 0.00.

153.847Direkt (D) Nein
F1, F2
  • F1 These shares represent restricted stock units (RSUs) granted under the Celularity Inc. 2021 Equity Incentive Plan (the 2021 Plan), with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest immediately upon grant.
  • F2 Includes 28,847 RSUs granted under the 2021 Plan, with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest immediately upon grant.
Einreichung öffnen 0001493152-26-002423 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
12. Jan. 2026 Eingereicht am 15. Jan. 2026Diamandis Peter Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Class A Common Stock
Erworben (A)20.3850,00
0

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 0.00.

394.150Direkt (D) Nein
F1, F2
  • F1 These shares represent restricted stock units (RSUs) granted under the Celularity Inc. 2021 Equity Incentive Plan (the 2021 Plan), with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest immediately upon grant.
  • F2 Includes 20,385 RSUs granted under the 2021 Plan, with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest immediately upon grant.
Einreichung öffnen 0001493152-26-002425 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
12. Jan. 2026 Eingereicht am 14. Jan. 2026Parks Diane L. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Class A Common Stock
Erworben (A)30.0000—520.021Direkt (D) Nein
F1, F2
  • F1 These shares represent restricted stock units (RSUs) granted under the Celularity Inc. 2021 Equity Incentive Plan (the 2021 Plan), with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date.
  • F2 Includes 30,000 RSUs granted under the 2021 Plan, with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date.
Einreichung öffnen 0001493152-26-002297 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
12. Jan. 2026 Eingereicht am 14. Jan. 2026LeVien Vincent Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Class A Common Stock
Erworben (A)28.8470—153.847Direkt (D) Nein
F1, F2
  • F1 These shares represent restricted stock units (RSUs) granted under the Celularity Inc. 2021 Equity Incentive Plan (the 2021 Plan), with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date.
  • F2 Includes 28,847 RSUs granted under the 2021 Plan, with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date.
Einreichung öffnen 0001493152-26-002300 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
12. Jan. 2026 Eingereicht am 14. Jan. 2026Diamandis Peter Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Class A Common Stock
Erworben (A)20.3850—394.150Direkt (D) Nein
F1, F2
  • F1 These shares represent restricted stock units (RSUs) granted under the Celularity Inc. 2021 Equity Incentive Plan (the 2021 Plan), with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date.
  • F2 Includes 20,385 RSUs granted under the 2021 Plan, with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date.
Einreichung öffnen 0001493152-26-002298 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
12. Jan. 2026 Eingereicht am 14. Jan. 2026Ling Geoffrey M.D. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Class A Common Stock
Erworben (A)19.2310,00
0

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 0.00.

256.026Direkt (D) Nein
F1, F2
  • F1 These shares represent restricted stock units (RSUs) granted under the Celularity Inc. 2021 Equity Incentive Plan (the 2021 Plan), with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date.
  • F2 Includes 19,231 RSUs granted under the 2021 Plan, with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date.
Einreichung öffnen 0001493152-26-002303 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
29. Dez. 2025 Eingereicht am 30. Dez. 2025Parks Diane L. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Class A Common Stock
Erworben (A)125.0000,00
0

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 0.00.

490.021Direkt (D) Nein
F1, F2
  • F1 These shares represent restricted stock units (RSUs) granted under the Celularity Inc. 2021 Equity Incentive Plan (the 2021 Plan), with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date.
  • F2 Includes 125,000 RSUs granted under the 2021 Plan, with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date.
Einreichung öffnen 0001493152-25-029615 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
29. Dez. 2025 Eingereicht am 30. Dez. 2025Parks Diane L. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivatives Wertpapier: Stock Options — Basiswert Class A Common Stock (156.250) — Ausübungspreis 1.20
Erworben (A)156.2500—518.774Direkt (D) Nein
F3
  • F3 This option was granted under the 2021 Plan and shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date.
Einreichung öffnen 0001493152-25-029615 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
29. Dez. 2025 Eingereicht am 30. Dez. 2025Diamandis Peter Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Class A Common Stock
Erworben (A)125.0000,00
0

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 0.00.

373.765Direkt (D) Nein
F1, F2
  • F1 These shares represent restricted stock units (RSUs) granted under the Celularity Inc. 2021 Equity Incentive Plan (the 2021 Plan), with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date.
  • F2 Includes 125,000 RSUs granted under the 2021 Plan, with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date.
Einreichung öffnen 0001493152-25-029614 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
29. Dez. 2025 Eingereicht am 30. Dez. 2025Diamandis Peter Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivatives Wertpapier: Stock Options — Basiswert Class A Common Stock (156.250) — Ausübungspreis 1.20
Erworben (A)156.2500—518.774Direkt (D) Nein
F3
  • F3 This option was granted under the 2021 Plan and shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date.
Einreichung öffnen 0001493152-25-029614 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
29. Dez. 2025 Eingereicht am 30. Dez. 2025LeVien Vincent Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Class A Common Stock
Erworben (A)125.0000,00
0

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 0.00.

125.000Direkt (D) Nein
F1, F2
  • F1 These shares represent restricted stock units (RSUs) granted under the Celularity Inc. 2021 Equity Incentive Plan (the 2021 Plan), with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date.
  • F2 Includes 125,000 RSUs granted under the 2021 Plan, with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date.
Einreichung öffnen 0001493152-25-029618 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
29. Dez. 2025 Eingereicht am 30. Dez. 2025LeVien Vincent Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivatives Wertpapier: Stock Options — Basiswert Class A Common Stock (156.250) — Ausübungspreis 1.20
Erworben (A)156.2500—156.250Direkt (D) Nein
F3
  • F3 This option was granted under the 2021 Plan and shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date.
Einreichung öffnen 0001493152-25-029618 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
29. Dez. 2025 Eingereicht am 30. Dez. 2025Ling Geoffrey M.D. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Class A Common Stock
Erworben (A)125.0000,00
0

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 0.00.

236.795Direkt (D) Nein
F1, F2
  • F1 These shares represent restricted stock units (RSUs) granted under the Celularity Inc. 2021 Equity Incentive Plan (the 2021 Plan), with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date.
  • F2 Includes 125,000 RSUs granted under the 2021 Plan, with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date.
Einreichung öffnen 0001493152-25-029617 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
29. Dez. 2025 Eingereicht am 30. Dez. 2025Ling Geoffrey M.D. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivatives Wertpapier: Stock Options — Basiswert Class A Common Stock (156.250) — Ausübungspreis 1.20
Erworben (A)156.2500—1.490.996Direkt (D) Nein
F3
  • F3 This option was granted under the 2021 Plan and shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date.
Einreichung öffnen 0001493152-25-029617 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
19. Dez. 2025 Eingereicht am 22. Dez. 2025Ling Geoffrey M.D. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Class A Common Stock
Erworben (A)67.4160,00
0

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 0.00.

111.795Direkt (D) Nein
F1
  • F1 These shares represent restricted stock units (RSUs) granted under the Celularity Inc. 2021 Equity Incentive Plan (the 2021 Plan), with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs vested on December 19, 2025.
Einreichung öffnen 0001493152-25-028780 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
19. Dez. 2025 Eingereicht am 22. Dez. 2025Parks Diane L. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Class A Common Stock
Erworben (A)67.4160,00
0

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 0.00.

365.021Direkt (D) Nein
F1
  • F1 These shares represent restricted stock units (RSUs) granted under the Celularity Inc. 2021 Equity Incentive Plan (the 2021 Plan), with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs vested and became exercisable on December 19, 2025.
Einreichung öffnen 0001493152-25-028787 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
19. Dez. 2025 Eingereicht am 22. Dez. 2025Diamandis Peter Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Class A Common Stock
Erworben (A)67.4160,00
0

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 0.00.

248.765Direkt (D) Nein
F1
  • F1 These shares represent restricted stock units (RSUs) granted under the Celularity Inc. 2021 Equity Incentive Plan (the 2021 Plan), with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs vested on December 19, 2025.
Einreichung öffnen 0001493152-25-028778 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
19. Nov. 2025 Eingereicht am 21. Nov. 2025Diamandis Peter Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Class A Common Stock
Erworben (A)47.0420,00
0

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 0.00.

248.765Direkt (D) Nein
F1
  • F1 These shares represent restricted stock units (RSUs) granted under the Celularity Inc. 2021 Equity Incentive Plan (the 2021 Plan), with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest and become exercisable on the date of grant.
Einreichung öffnen 0001493152-25-024630 Aus dem XML der Einreichung gelesen Diese Zeile anfechten

Institutionelle Halter (Formular 13F)

Quartal zum 2026-09-30: 7.211 Einreichungen gelesen, die jüngste vom 13. Nov. 2026. Vorquartal zum 2026-06-30: 9.150 Einreichungen gelesen.

1–30 von 30 angezeigt

Institutionelle Halter, größte Position zuerst, wie eingereicht
ManagerAktien oder NennbetragWert wie eingereichtDifferenz zum VorquartalQuelle
C V STARR CO INC 764.069 SH1.031.494 DollarUnverändert Vorquartal: 764.069Einreichung öffnen 0001140361-26-043078 Eingereicht am 10. Nov. 2026 Diese Zeile anfechten
VANGUARD CAPITAL MANAGEMENT LLC 646.444 SH872.699 DollarHöher um 25.339 Vorquartal: 621.105Einreichung öffnen 0002100119-26-001711 Eingereicht am 13. Nov. 2026 Diese Zeile anfechten
GEODE CAPITAL MANAGEMENT, LLC Teilweise unter einem anderen Manager gemeldet167.150 SH225.697 DollarUnverändert Vorquartal: 167.150Einreichung öffnen 0001214717-26-000012 Eingereicht am 6. Nov. 2026 Diese Zeile anfechten
VANGUARD FIDUCIARY TRUST CO 121.516 SH164.047 DollarHöher um 41.642 Vorquartal: 79.874Einreichung öffnen 0000933478-26-000017 Eingereicht am 13. Nov. 2026 Diese Zeile anfechten
UBS Group AG Teilweise unter einem anderen Manager gemeldet80.075 SH108.101 DollarHöher um 73.117 Vorquartal: 6.958Einreichung öffnen 0001610520-26-000121 Eingereicht am 10. Nov. 2026 Diese Zeile anfechten
BlackRock, Inc. Teilweise unter einem anderen Manager gemeldet76.359 SH103.085 DollarUnverändert Vorquartal: 76.359Einreichung öffnen 0002012383-26-003985 Eingereicht am 13. Nov. 2026 Diese Zeile anfechten
STATE STREET CORP Teilweise unter einem anderen Manager gemeldet57.830 SH78.071 DollarUnverändert Vorquartal: 57.830Einreichung öffnen 0000093751-26-000747 Eingereicht am 12. Nov. 2026 Diese Zeile anfechten
Biltmore Family Office, LLC 35.000 SH47.250 DollarUnverändert Vorquartal: 35.000Einreichung öffnen 0001398344-26-019404 Eingereicht am 3. Nov. 2026 Diese Zeile anfechten
HB Wealth Management, LLC 31.915 SH43.085 DollarUnverändert Vorquartal: 31.915Einreichung öffnen 0001172661-26-004668 Eingereicht am 23. Okt. 2026 Diese Zeile anfechten
Sky Investment Group LLC 29.920 SH40.392 DollarNicht in den gelesenen Einreichungen des Vorquartals Einreichung öffnen 0001941040-26-000786 Eingereicht am 30. Okt. 2026 Diese Zeile anfechten
JANE STREET GROUP, LLC Teilweise unter einem anderen Manager gemeldet17.403 SH23.494 DollarNiedriger um 11.310 Vorquartal: 28.713Einreichung öffnen 0001595888-26-000162 Eingereicht am 12. Nov. 2026 Diese Zeile anfechten
IPG Investment Advisors LLC 17.169 SH23.178 DollarUnverändert Vorquartal: 17.169Einreichung öffnen 0001602237-26-000008 Eingereicht am 30. Okt. 2026 Diese Zeile anfechten
GROUP ONE TRADING LLC Option: Call 9.700 SH13.095 DollarNicht in den gelesenen Einreichungen des Vorquartals Einreichung öffnen 0000932540-26-000017 Eingereicht am 10. Nov. 2026 Diese Zeile anfechten
BFC Planning, Inc. 7.713 SH10.413 DollarUnverändert Vorquartal: 7.713Einreichung öffnen 0001420506-26-002645 Eingereicht am 13. Nov. 2026 Diese Zeile anfechten
SIMPLEX TRADING, LLC Option: Call 6.000 SH8.100 DollarNicht in den gelesenen Einreichungen des Vorquartals Einreichung öffnen 0001488542-26-000013 Eingereicht am 4. Nov. 2026 Diese Zeile anfechten
Vanguard Global Advisers, LLC 2.315 SH3.125 DollarUnverändert Vorquartal: 2.315Einreichung öffnen 0001811242-26-000017 Eingereicht am 13. Nov. 2026 Diese Zeile anfechten
SBI Securities Co., Ltd. 1.882 SH2.541 DollarNiedriger um 402 Vorquartal: 2.284Einreichung öffnen 0001851815-26-000004 Eingereicht am 22. Okt. 2026 Diese Zeile anfechten
CALDWELL SUTTER CAPITAL, INC. 1.000 SH1.350 DollarUnverändert Vorquartal: 1.000Einreichung öffnen 0000702007-26-000013 Eingereicht am 9. Nov. 2026 Diese Zeile anfechten
CoreCap Advisors, LLC 500 SH675 DollarUnverändert Vorquartal: 500Einreichung öffnen 0001902501-26-000006 Eingereicht am 8. Okt. 2026 Diese Zeile anfechten
Global Retirement Partners, LLC 300 SH405 DollarUnverändert Vorquartal: 300Einreichung öffnen 0001580642-26-007620 Eingereicht am 10. Nov. 2026 Diese Zeile anfechten
Financial Perspectives, Inc 171 SH231 DollarUnverändert Vorquartal: 171Einreichung öffnen 0002003287-26-000005 Eingereicht am 3. Nov. 2026 Diese Zeile anfechten
SIMPLEX TRADING, LLC Option: Put 100 SH135 DollarNicht in den gelesenen Einreichungen des Vorquartals Einreichung öffnen 0001488542-26-000013 Eingereicht am 4. Nov. 2026 Diese Zeile anfechten
VALLEY NATIONAL ADVISERS INC 100 SH135 DollarUnverändert Vorquartal: 100Einreichung öffnen 0000773411-26-000007 Eingereicht am 23. Okt. 2026 Diese Zeile anfechten
BNP PARIBAS FINANCIAL MARKETS Teilweise unter einem anderen Manager gemeldet99 SH134 DollarUnverändert Vorquartal: 99Einreichung öffnen 0001166588-26-000012 Eingereicht am 12. Nov. 2026 Diese Zeile anfechten
JONES FINANCIAL COMPANIES LLLP Teilweise unter einem anderen Manager gemeldet82 SH113 DollarUnverändert Vorquartal: 82Einreichung öffnen 0001193125-26-459442 Eingereicht am 13. Nov. 2026 Diese Zeile anfechten
United Financial Planning Group LLC 19 SH26 DollarUnverändert Vorquartal: 19Einreichung öffnen 0002088337-26-000008 Eingereicht am 4. Nov. 2026 Diese Zeile anfechten
JPMORGAN CHASE CO Teilweise unter einem anderen Manager gemeldet16 SH22 DollarUnverändert Vorquartal: 16Einreichung öffnen 0000019617-26-000404 Eingereicht am 12. Nov. 2026 Diese Zeile anfechten
HARBOUR INVESTMENTS, INC. 15 SH20 DollarUnverändert Vorquartal: 15Einreichung öffnen 0000810121-26-000006 Eingereicht am 9. Nov. 2026 Diese Zeile anfechten
BARCLAYS PLC Teilweise unter einem anderen Manager gemeldet4 SH5 DollarNicht in den gelesenen Einreichungen des Vorquartals Einreichung öffnen 0000312069-26-000241 Eingereicht am 6. Nov. 2026 Diese Zeile anfechten
DANSKE BANK A/S 1 SH1 DollarUnverändert Vorquartal: 1Einreichung öffnen 0001104659-26-124081 Eingereicht am 9. Nov. 2026 Diese Zeile anfechten
Manager des Vorquartals ohne gelesene Einreichung für das neueste

Sie haben möglicherweise nur noch nicht eingereicht: Das Fehlen in den gelesenen Einreichungen des neuesten Quartals bedeutet nicht, dass die Position verkauft wurde.

  • Walleye Capital LLC 835.194 SH
  • Linden Advisors LP 550.119 SH
  • HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND 350.000 SH
  • PEAK6 LLC 171.363 SH
  • Davidson Kempner Capital Management LP 150.800 SH
  • Context Capital Management, LLC 150.000 SH
  • CITADEL ADVISORS LLC 99.054 SH
  • Lombard Odier Asset Management (Europe) Ltd 84.919 SH
  • TWO SIGMA SECURITIES, LLC 65.609 SH
  • HRT FINANCIAL LP 56.591 SH
  • Corient Private Wealth LP 50.000 SH
  • NORTHERN TRUST CORP 44.163 SH
  • KEYNOTE FINANCIAL SERVICES LLC 29.920 SH
  • CenterStar Asset Management, LLC 21.000 SH
  • Virtu Financial LLC 18.697 SH
  • ROYAL BANK OF CANADA 18.000 SH
  • CenterStar Asset Management, LLC 15.000 SH
  • SUSQUEHANNA INTERNATIONAL GROUP, LLP 14.619 SH
  • IFP Advisors, Inc 12.000 SH
  • Clear Street Group Inc. 11.613 SH
  • Weaver Capital Management LLC 11.609 SH
  • Procyon Advisors, LLC 11.500 SH
  • Tower Research Capital LLC (TRC) 5.111 SH
  • GROUP ONE TRADING LLC 3.595 SH
  • WELLS FARGO COMPANY/MN 2.500 SH
  • SIMPLEX TRADING, LLC 2.188 SH
  • HighMark Wealth Management LLC 441 SH
  • MERCER GLOBAL ADVISORS INC /ADV 100 SH
  • WOLVERINE ASSET MANAGEMENT LLC 68 SH
  • MORGAN STANLEY 21 SH
  • TORNO CAPITAL, LLC 1 SH
  • Das Formular 13F umfasst nur Long-Positionen in Wertpapieren nach Section 13(f): keine Short-Positionen und keine Wertpapiere außerhalb dieser Liste.
  • Ein Manager, der für das neueste Quartal noch nicht eingereicht hat, fehlt und steht nicht bei null; die Frist beträgt bis zu 45 Tage nach Quartalsende.
  • Eine Differenz ist der Unterschied zwischen zwei Quartalsstichtagen, keine Transaktion.
  • Eine unter einem anderen Manager gemeldete Position kann auch in dessen Einreichung erscheinen; die Zeilen werden nicht addiert.
  • Positionen, die die Wertpapierliste diesem Unternehmen nicht oder nur mehrdeutig zuordnen kann, werden nicht angezeigt.

5-%-Halter (Schedule 13D und 13G)

Hier werden im strukturierten SEC-Format (ab Ende 2024) eingereichte Schedules gelesen. Frühere sind Freitext und werden nicht gelesen.

5-%-Halter, jüngstes Ereignis zuerst, wie eingereicht
HalterProzent der GattungGehaltene AktienEreignisdatumFormularQuelle
PHILIP DANIELE BARACH FAMILY TRUST Class A Common Stock, Par Value $0.0001 Per Share29.011.940.187,0009/23/2026 Eingereicht am 28. Sept. 2026SCHEDULE 13D/AÄnderung 3Einreichung öffnen 0001104659-26-111279 Diese Zeile anfechten
PHILIP A. BARACH Class A Common Stock, Par Value $0.0001 Per Share29.011.940.187,0009/23/2026 Eingereicht am 28. Sept. 2026SCHEDULE 13D/AÄnderung 3Einreichung öffnen 0001104659-26-111279 Diese Zeile anfechten
DANIELE BARACH Class A Common Stock, Par Value $0.0001 Per Share29.011.940.187,0009/23/2026 Eingereicht am 28. Sept. 2026SCHEDULE 13D/AÄnderung 3Einreichung öffnen 0001104659-26-111279 Diese Zeile anfechten
PHILIP DANIELE BARACH FAMILY TRUST Class A Common Stock, Par Value $0.0001 Per Share15.85.514.686,0006/19/2026 Eingereicht am 23. Juni 2026SCHEDULE 13D/AÄnderung 2Einreichung öffnen 0001104659-26-076580 Diese Zeile anfechten
PHILIP A. BARACH Class A Common Stock, Par Value $0.0001 Per Share15.85.514.686,0006/19/2026 Eingereicht am 23. Juni 2026SCHEDULE 13D/AÄnderung 2Einreichung öffnen 0001104659-26-076580 Diese Zeile anfechten
DANIELE BARACH Class A Common Stock, Par Value $0.0001 Per Share15.85.514.686,0006/19/2026 Eingereicht am 23. Juni 2026SCHEDULE 13D/AÄnderung 2Einreichung öffnen 0001104659-26-076580 Diese Zeile anfechten
PHILIP DANIELE BARACH FAMILY TRUST Class A Common Stock, Par Value $0.0001 Per Share20.17.558.665,0004/20/2026 Eingereicht am 22. Apr. 2026SCHEDULE 13D/AÄnderung 1Einreichung öffnen 0001104659-26-046494 Diese Zeile anfechten
PHILIP A. BARACH Class A Common Stock, Par Value $0.0001 Per Share20.17.558.665,0004/20/2026 Eingereicht am 22. Apr. 2026SCHEDULE 13D/AÄnderung 1Einreichung öffnen 0001104659-26-046494 Diese Zeile anfechten
DANIELE BARACH Class A Common Stock, Par Value $0.0001 Per Share20.17.558.665,0004/20/2026 Eingereicht am 22. Apr. 2026SCHEDULE 13D/AÄnderung 1Einreichung öffnen 0001104659-26-046494 Diese Zeile anfechten
PHILP DANIELE BARACH FAMILY TRUST Class A Common Stock, Par Value $0.0001 Per Share9.563.012.048,0012/19/2025 Eingereicht am 3. Apr. 2026SCHEDULE 13DEinreichung öffnen 0001104659-26-039490 Diese Zeile anfechten
PHILIP A. BARACH Class A Common Stock, Par Value $0.0001 Per Share9.563.012.048,0012/19/2025 Eingereicht am 3. Apr. 2026SCHEDULE 13DEinreichung öffnen 0001104659-26-039490 Diese Zeile anfechten
DANIELE BARACH Class A Common Stock, Par Value $0.0001 Per Share9.563.012.048,0012/19/2025 Eingereicht am 3. Apr. 2026SCHEDULE 13DEinreichung öffnen 0001104659-26-039490 Diese Zeile anfechten
Dragasac Limited Class A Common Stock, par value $0.0001 per share23.86.335.63007/24/2025 Eingereicht am 28. Juli 2025SCHEDULE 13D/AÄnderung 6Einreichung öffnen 0000905148-25-002573 Diese Zeile anfechten
Resorts World Inc Pte. Ltd. Class A Common Stock, par value $0.0001 per share13.34.100.00007/24/2025 Eingereicht am 28. Juli 2025SCHEDULE 13D/AÄnderung 6Einreichung öffnen 0000905148-25-002573 Diese Zeile anfechten
Genting Berhad Class A Common Stock, par value $0.0001 per share33.910.435.63007/24/2025 Eingereicht am 28. Juli 2025SCHEDULE 13D/AÄnderung 6Einreichung öffnen 0000905148-25-002573 Diese Zeile anfechten
Lim Kok Thay Class A Common Stock, par value $0.0001 per share4114.138.16107/24/2025 Eingereicht am 28. Juli 2025SCHEDULE 13D/AÄnderung 6Einreichung öffnen 0000905148-25-002573 Diese Zeile anfechten
Lincoln Alternative Strategies LLC Class A Common Stock, $0.0001 par value per share00,0007/14/2025 Eingereicht am 11. Feb. 2026SCHEDULE 13G/AÄnderung 1Einreichung öffnen 0001493152-26-006196 Diese Zeile anfechten
Lincoln Alternative Strategies LLC Class A Common Stock, $0.0001 par value per share5.141.230.769,0007/14/2025 Eingereicht am 27. Aug. 2025SCHEDULE 13GEinreichung öffnen 0001641172-25-025647 Diese Zeile anfechten

Der Prozentsatz bezieht sich auf die in der Einreichung genannte Gattung, wie vom Halter angegeben. Gruppenmitglieder melden jeweils die Aktien der Gruppe; die Zeilen werden daher nicht addiert.

Was gelesen wurde

2.119.757 Einreichungen gelesen, vom 14. Juni 2004 bis 13. Nov. 2026: Formulare 3, 3/A, 4, 4/A, 5, 5/A.

Jahre können unvollständig sein, solange das Archiv noch gelesen wird. Ein Jahr mit wenigen Einreichungen hier besagt nicht, dass wenige gemacht wurden.

Gelesene Einreichungen nach Einreichungsjahr
EinreichungsjahrGelesene Einreichungen
20151
2016204.322
2017202.494
2018202.048
2019193.638
2020144.184
2021224.474
202242.927
2023199.811
2024209.823
2025235.520
2026254.737

Einreichungen aus der Zeit vor der XML-Pflicht der SEC sind aufgeführt, aber nicht ausgelesen.

Zurück zu Celularity Inc